#clinical-stage-biotech

[ follow ]
#stat6-degrader #oral-immunotherapy #type-2-inflammation #irf5-directed-therapy #analyst-price-targets
Venture
from24/7 Wall St.
4 days ago

Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss

Kymera Therapeutics advanced the first IRF5-directed therapy into human trials and progressed KT-621, an oral STAT6 degrader showing efficacy comparable to dupilumab with potential to treat millions of undertreated Type 2 inflammatory disease patients.
Business
from24/7 Wall St.
3 weeks ago

Wall Street Thinks These 4 Biotech Stocks Will Double--At Least--This Year

Wall Street analysts assign unanimous or near-unanimous Buy ratings to four clinical-stage biotech companies, implying potential gains up to 384% driven by late-stage pipelines and upcoming catalysts.
[ Load more ]